Alamar Biosciences (NASDAQ:ALMR) Posts Earnings Results

Alamar Biosciences (NASDAQ:ALMR) issued its quarterly earnings data on Friday. The company reported ($1.74) earnings per share for the quarter, Zacks reports. The company had revenue of $26.04 million during the quarter.

Alamar Biosciences Stock Up 5.1%

NASDAQ ALMR traded up $1.21 during trading on Friday, hitting $24.87. The company’s stock had a trading volume of 177,151 shares, compared to its average volume of 352,646. Alamar Biosciences has a 52 week low of $21.50 and a 52 week high of $27.20.

Insider Buying and Selling at Alamar Biosciences

In related news, major shareholder Innovation Fund Gp Illumina II purchased 235,294 shares of Alamar Biosciences stock in a transaction on Monday, April 20th. The stock was purchased at an average cost of $17.00 per share, with a total value of $3,999,998.00. Following the acquisition, the insider directly owned 507,076 shares in the company, valued at approximately $8,620,292. This trade represents a 86.57% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Nicholas Naclerio purchased 235,294 shares of the firm’s stock in a transaction on Monday, April 20th. The stock was bought at an average price of $17.00 per share, for a total transaction of $3,999,998.00. Following the completion of the transaction, the director directly owned 507,076 shares in the company, valued at approximately $8,620,292. The trade was a 86.57% increase in their ownership of the stock. The SEC filing for this purchase provides additional information.

Analysts Set New Price Targets

Separately, Wall Street Zen raised Alamar Biosciences to a “hold” rating in a research note on Saturday, April 25th.

Alamar Biosciences Company Profile

Our mission is to power precision proteomics to enable the earliest detection of disease. We are a commercial-stage proteomics company establishing a gold standard in protein detection and analysis. Our proprietary NULISA technology was purpose-built to address the limitations of existing proteomics tools by detecting protein biomarkers at extremely low concentrations in non-invasive biological fluids, such as blood, with ultra-high sensitivity, high specificity, flexible multiplexing, broad dynamic range and seamless automation.